Much of the experimental evidence in the literature has linked
altered lipid metabolism to severe diseases such as cancer, obesity,
cardiovascular pathologies, diabetes, and neurodegenerative diseases.
Therefore, targeting key effectors of the dysregulated lipid metabolism
may represent an effective strategy to counteract these pathological
conditions. In this context, α/β-hydrolase domain (ABHD)
enzymes represent an important and diversified family of proteins,
which are involved in the complex environment of lipid signaling,
metabolism, and regulation. Moreover, some members of the ABHD family
play an important role in the endocannabinoid system, being designated
to terminate the signaling of the key endocannabinoid regulator 2-arachidonoylglycerol.
This Perspective summarizes the research progress in the development
of ABHD inhibitors and modulators: design strategies, structure–activity
relationships, action mechanisms, and biological studies of the main
ABHD ligands will be highlighted.